Skip to main content

Table 1 Clinicopathological parameters and association with BRCA1/BRCA2 carriers

From: Novel and recurrent BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer: a series from the south of Tunisia

  N (%) Non carrier (%) BRCA1 carrier (%) BRCA2 carrier (%) p
Family history
 Yes 113 (84.3) 95 (84) 9 (8) 9(8) 0.33
 No 21 (15.7) 20 (95.2) 1 (4.8) 0 (0.00)  
Age
 ≤ 30 9 (6.7) 7 (77.8) 1 (11.1) 1(11.1) 0.433
 31–40 55 (41) 45 (81.8) 7 (12.7) 3 (5.5)  
 41–50 33 (24.6) 29 (87.9) 2 (6.1) 2 (6.1)  
 ≥ 51 37 (27.6) 34 (91.9) 0 (0.00) 3 (8.1)  
Tumor site
 Unilateral BC 104 (77.6) 92 (88.5) 4 (3.8) 8 (7.7) 0.029
 Bilateral BC 6 (4.5) 4 (66.7) 1 (16.7) 1 (16.7)  
 OC 22 (16.4) 18 (81.8) 4 (18.2) 0 (0.00)  
 OC/BC 2 (1.5) 1(50) 1 (50) 0 (0.00)  
Tumor grade
 SBR II 82 (73.2) 73 (89) 4 (4.9) 5 (6.1) 0.41
 SBR III 30 (26.8) 24 (80) 2 (6.7) 4 (13.3)  
T-stage
 T0–T1 11 (8.2) 9 (81.8) 2 (18.2) 0 (0.00) 0.16
 T2 63 (47) 56 (88.9) 2 (3.2) 5(7.9)  
 T3 49 (36.6) 41 (83.7) 6 (12.2) 2 (4.1)  
 T4 11 (8.2) 9 (81.8) 0 (0.00) 2 (18.2)  
N-stage
 No 54 (40.3) 48 (88.9) 3 (5.6) 3 (5.6) 0.69
 N1–N2 80 (59.7) 67 (83.8) 7 (8.8) 6 (7.5)  
M
 M0 120 (89.6) 105 (87.5) 7 (5.8) 8 (6.7) 0.107
 M1 14 (10.4) 10 (71.4) 3 (21.4) 1 (7.1)  
Triple negative
 No 84 (76.4) 75 (89.3) 1 (1.2) 8 (9.5) 0.008
 Yes 26 (23.6) 21 (80.8) 4 (15.4) 1 (3.8)